We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$465M
Cap. Flow %
-8.83%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.8B
$358M 6.8%
3,719,173
-127,500
-3% -$14.2M
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
$343M 6.51%
11,114,280
– –
BSX icon
3
Boston Scientific
BSX
$68.3B
$214M 4.07%
5,268,700
-1,483,800
-22% -$62.9M
ALEC icon
4
Alector
ALEC
$167M
$181M 3.43%
12,532,329
-650,000
-5% -$11.7M
PRVL
5
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$170M 3.22%
13,822,463
– –
MRK icon
6
Merck
MRK
$324B
$164M 3.12%
2,047,897
-645,568
-24% -$51.7M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$163M 3.09%
1,663,285
-262,800
-14% -$29.6M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$161M 3.05%
+7,406,307
New +$175M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$125B
$143M 2.72%
846,400
-126,900
-13% -$22.4M
NBIX icon
10
Neurocrine Biosciences
NBIX
$18.2B
$142M 2.69%
1,575,170
-258,030
-14% -$24.1M
EW icon
11
Edwards Lifesciences
EW
$48.5B
$112M 2.12%
1,523,400
-621,600
-29% -$43.7M
ISRG icon
12
Intuitive Surgical
ISRG
$128B
$111M 2.11%
616,800
-14,100
-2% -$2.44M
TPTX
13
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$103M 1.96%
2,745,327
+177,777
+7% +$7.74M
TMO icon
14
Thermo Fisher Scientific
TMO
$215B
$102M 1.94%
351,900
-110,900
-24% -$31.8M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.05B
$101M 1.92%
5,548,326
– –
NTRA icon
16
Natera
NTRA
$36B
$98.4M 1.87%
3,000,128
-224,200
-7% -$6.63M
AVDR
17
DELISTED
Avedro, Inc Common Stock
AVDR
$96.3M 1.83%
4,240,128
– –
INSP icon
18
Inspire Medical Systems
INSP
$1.5B
$89.8M 1.7%
1,471,000
– –
THOR
19
DELISTED
Synthorx, Inc. Common Stock
THOR
$86.5M 1.64%
5,316,355
– –
NXTC icon
20
NextCure
NXTC
$20.9M
$83.6M 1.59%
225,918
– –
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$83.5M 1.58%
2,460,571
-1,157,600
-32% -$34.3M
WMGI
22
DELISTED
Wright Medical Group Inc
WMGI
$79.2M 1.5%
3,837,250
-350,549
-8% -$8.34M
EHTH icon
23
eHealth
EHTH
$43.5M
$74.6M 1.42%
1,117,414
+207,600
+23% +$18.7M
BHC icon
24
Bausch Health
BHC
$1.68B
$72.4M 1.37%
3,312,300
-428,400
-11% -$9.8M
LOGC
25
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$69.9M 1.33%
6,466,783
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $465M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.